Program

8.30 Breakfast and networking

9.00 Welcome to the event
Ouli Uimonen, CEO, Pharmaca Health Intelligence 

9.10 Fundamentals of Quantum Technology from the Perspective of the Pharmaceutical Industry
Sabrina Maniscalco, Professor, University of Helsinki

The fundamentals of quantum technology from the perspective of the pharmaceutical industry open up entirely new possibilities for faster research and stronger breakthroughs. Quantum computing can radically accelerate molecular simulations, speeding up the critical phases of drug development.

9.50 Finland's Quantum Technology Strategy
Martti Myllylä, Negotiating official, Ministry of Economic Affairs and Employment

Investing in quantum expertise is a strategic choice for Finland. Finland’s key competitive advantage lies in its well‑functioning national ecosystem, whose strong capabilities are built on decades of research across scientific and technological fields that support the development of quantum technologies. Finland is also one of the few countries capable of producing complete quantum computers.

10.20 Networking

10.40 Quantum Revolution
Mikko Möttönen, Full Professor of Quantum Technology, Aalto University

The Quantum Revolution is here — transforming computing, communication, and sensing with breakthroughs that push far beyond the limits of classical technology. 
This shift empowering innovators to solve challenges once thought impossible.

11.20 Quantum technology in pharmaceutical development
Michael Streif, Quantum Computing Scientist, Boehringer Ingelheim

In this session, the transformative potential of quantum technology in pharmaceutical development is explored. The presentation highlights how quantum computing can enhance molecular modelling, accelerate the identification of new drug candidates, and improve the efficiency of research and development processes.

12.00-13.00 Lunch and networking

13.00 Safety of future technologies
Ilja Sidoroff, Senior Specialist, National Cyber Security Centre / Finnish Transport and
Communications Agency Traficom

Explores the safety aspects of emerging technologies, focusing on how new innovations can both enhance protection and introduce new risks, and highlighting the importance of managing these risks in rapidly evolving technological environments.

13.40 The Journey from Care to Evidence: Tackling Registry Hurdles
Hanna Heloterä, Senior Consultant, Pharmaca

This presentation highlights the increasing importance of registry data in supporting modern healthcare objectives such as data‑driven management, value‑based healthcare, and regulatory compliance.
• Although registry and hospital data were originally collected for immediate clinical care, their secondary use for research and operational decision‑making has expanded rapidly.
• This shift places new demands on data accuracy, completeness, and system design.
• Ultimately, high‑quality data benefits all parties—clinicians, researchers, administrators, and patients. Improving registry accuracy requires collaboration, shared expertise, and continuous development of health information systems.

14.20 Coffee and networking

14.50 Session will be updated soon

15.30 Thank you for participating!